alexa Singapore Immunology Networks Clinical Immunomonitoring Platform For The Assessment Of Immune Responses In Cohort Studies And Clinical Trials
ISSN: 2157-7560

Journal of Vaccines & Vaccination
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

16th Euro Global Summit and Expo on Vaccines & Vaccination
June 19-21, 2017 Paris, France

Brian Abel
A*STAR, Singapore
ScientificTracks Abstracts: J Vaccines Vaccin
DOI: 10.4172/2157-7560-C1-057
The clinical immunomonitoring platform at the Singapore Immunology Network (SIgN) is dedicated to defining immunomarkers and immunological endpoints with clinically relevant impact via high-throughput acquisition of immunological data from cohort studies and clinical trials. The platform leverages on the scientific expertise of principal investigators (PI) supported by a suite of capabilities including the following facilities: flow cytometry/FACS/luminex, CyTOF, immunogenomics, and a comprehensive bioinformatics team. The platform may be involved from the initial stage of study design to sample processing, bio-banking, assay running and ultimately, downstream analysis. The complex datasets generated from the measurement of immune and clinical parameters are integrated into the translational data warehousing system, TranSMART, analyzed using well-established pipelines and interpreter. The platform has a well-defined workflow and project management infrastructure, which is capable of engaging all phases of research from early discovery all the way through to the assessment of phase IV clinical trials. The platform’s capabilities can be exploited to yield outcomes spanning diverse applications including biomarker discovery, novel target identification, technology development and the assessment of vaccine clinical trials. Examples of current clinical trials and studies conducted by the platform will be briefly discussed which include: (1) the assessment of responsiveness to flu vaccination in the elderly; (2) The longitudinal assessment of dengue natural infection vs. dengue vaccination; and (3) the assessment of tumor antigen-specific CTLs in syngeneic tumor models.

Brian Abel received his PhD in 2006 from the ETH, Zurich, and Post-doctoral studies from SATVI, University of Cape Town, where he worked on the immunological assessment of a novel TB vaccine in clinical trials and contributed to TB biomarker discovery. He completed an MBA from Tel Aviv University and ISB, Hyderabad, to facilitate a transition from academia into translational roles in Biomedical Science. He joined SIgN in 2012 to manage the immunomonitoring platform, conducting business development, project management and supporting finalization of agreements with industry partners, as well as acquiring regulatory approval for clinical research. In 2016, he became the Head of the Immunogenomics Core to support and drive genomic activities for SIgN's researchers and facilitate collaborations with industry partners.

Email: [email protected]

image PDF   |   image HTML
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version